Longitudinal Effects of Bumetanide on Neuro-Cognitive Functioning in Drug-Resistant Epilepsy.

GABA TRACULA bumetanide cognitive function drug-resistant epilepsy

Journal

Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899

Informations de publication

Date de publication:
2019
Historique:
received: 29 01 2019
accepted: 23 04 2019
entrez: 29 5 2019
pubmed: 28 5 2019
medline: 28 5 2019
Statut: epublish

Résumé

Antiepileptic drugs (AEDs) have repeatedly shown inconsistent and almost contradictory effects on the neurocognitive system, from substantial impairments in processing speed to the noticeable improvement in working memory and executive functioning. Previous studies have provided a novel insight into the cognitive improvement by bumetanide as a potential antiepileptic drug. Through the current investigation, we evaluated the longitudinal effects of bumetanide, an NKCC1 co-transporter antagonist, on the brain microstructural organization as a probable underlying component for cognitive performance. Microstructure assessment was completed using SPM for the whole brain assay and Freesurfer/TRACULA for the automatic probabilistic tractography analysis. Primary cognitive operations including selective attention and processing speed, working memory capacity and spatial memory were evaluated in 12 patients with a confirmed diagnosis of refractory epilepsy. Participants treated with bumetanide (2 mg/ day) in two divided doses as an adjuvant therapy to their regular AEDs for 6 months, which followed by the re-assessment of their cognitive functions and microstructural organizations. Seizure frequency reduced in eight patients which accompanied by white matter reconstruction; fractional anisotropy (FA) increased in the cingulum-cingulate gyrus (CCG), anterior thalamic radiation (ATR), and temporal part of the superior longitudinal fasciculus (SLFt) in correlation with the clinical response. The voxel-based analysis in responder patients revealed increased FA in the left hippocampus, right cerebellum, and right medial temporal lobe, while mean diffusivity (MD) values reduced in the right occipital lobe and cerebellum. Microstructural changes in SLFt and ATR accompanied by a reduction in the error rate in the spatial memory test. These primary results have provided preliminary evidence for the effect of bumetanide on cognitive functioning through microstructural changes in patients with drug-resistant epilepsy.

Identifiants

pubmed: 31133976
doi: 10.3389/fneur.2019.00483
pmc: PMC6517515
doi:

Types de publication

Journal Article

Langues

eng

Pagination

483

Références

Magn Reson Imaging. 2002 Sep;20(7):511-9
pubmed: 12413596
Epilepsy Behav. 2001 Feb;2(1):20-27
pubmed: 12609178
Neuroimage. 2003 Nov;20(3):1714-22
pubmed: 14642481
J Neurochem. 2004 Oct;91(1):238-51
pubmed: 15379904
FASEB J. 2004 Dec;18(15):1870-8
pubmed: 15576490
Diabetes. 2005 Feb;54(2):510-6
pubmed: 15677509
Epilepsia. 2005 May;46(5):760-6
pubmed: 15857444
Am J Physiol Cell Physiol. 2005 Dec;289(6):C1492-501
pubmed: 16079189
Nat Med. 2005 Nov;11(11):1205-13
pubmed: 16227993
Neuropsychobiology. 2006;53(3):157-68
pubmed: 16707915
Neuropharmacology. 2007 Sep;53(4):524-33
pubmed: 17681355
Neurology. 2008 Jan 1;70(1):54-65
pubmed: 18166707
Lancet Neurol. 2008 Dec;7(12):1099-105
pubmed: 18986841
Neuroimage. 2009 Jul 1;46(3):600-7
pubmed: 19264144
Magn Reson Med. 2009 Jun;61(6):1336-49
pubmed: 19319973
AJNR Am J Neuroradiol. 2009 Oct;30(9):1740-7
pubmed: 19509072
Epilepsia. 2010 Jan;51(1):48-56
pubmed: 19583779
Epilepsia. 2010 Jun;51(6):1069-77
pubmed: 19889013
Front Neuroinform. 2011 Oct 14;5:23
pubmed: 22016733
Ther Adv Neurol Disord. 2011 Nov;4(6):385-407
pubmed: 22164192
Curr Opin Neurol. 2012 Apr;25(2):194-200
pubmed: 22322414
Ann Neurol. 2012 Apr;71(4):539-51
pubmed: 22447678
Epilepsia. 2013 Jan;54(1):e9-12
pubmed: 23061490
Epilepsy Behav. 2013 Mar;26(3):410-4
pubmed: 23305781
Neuroimage. 2014 Mar;88:79-90
pubmed: 24269273
Brain Cogn. 2014 Feb;84(1):123-31
pubmed: 24362071
Neuroimage Clin. 2013 Dec 14;4:190-200
pubmed: 24392306
Epilepsia. 2014 Jun;55(6):806-18
pubmed: 24802699
Hum Brain Mapp. 2014 Jul;35(7):3332-42
pubmed: 25050427
Epilepsia. 2014 Oct;55(10):1576-84
pubmed: 25231724
Stroke. 2015 Feb;46(2):425-32
pubmed: 25572411
Nat Med. 2015 Apr;21(4):318-26
pubmed: 25774849
Quant Imaging Med Surg. 2015 Apr;5(2):238-46
pubmed: 25853082
Epileptic Disord. 2015 Jun;17(2):101-16
pubmed: 25905906
Epilepsia. 2015 Oct;56(10):1551-61
pubmed: 26249101
Clin Neuropharmacol. 2015 Sep-Oct;38(5):177-82
pubmed: 26366961
Neuroimage. 2016 Jan 15;125:1079-1094
pubmed: 26549300
Epilepsia. 2016 Feb;57(2):222-32
pubmed: 26659482
Epilepsy Res. 2016 Feb;120:65-72
pubmed: 26735187
PLoS One. 2016 Jan 11;11(1):e0146262
pubmed: 26752539
Clin Neuropharmacol. 2016 Jan-Feb;39(1):57-9
pubmed: 26757306
Epilepsy Behav. 2016 Feb;55:79-83
pubmed: 26773674
Clin Neuropharmacol. 2016 Mar-Apr;39(2):115-7
pubmed: 26966887
Cereb Cortex. 2017 Mar 1;27(3):2303-2317
pubmed: 27073220
Biomed Pharmacother. 2016 Jul;81:402-410
pubmed: 27261619
Hum Brain Mapp. 2017 Jan;38(1):561-573
pubmed: 27654880
Neuron. 2016 Oct 19;92(2):493-504
pubmed: 27720487
Neurotoxicol Teratol. 2017 Mar - Apr;60:82-86
pubmed: 27826117
Schizophr Res. 2017 Jun;184:145-146
pubmed: 27956008
Brain Imaging Behav. 2018 Feb;12(1):64-77
pubmed: 28102529
Neuroimage Clin. 2017 Jan 05;14:67-76
pubmed: 28138428
Transl Psychiatry. 2017 Mar 14;7(3):e1056
pubmed: 28291262
Front Aging Neurosci. 2017 Mar 16;9:59
pubmed: 28360853
Schizophr Res. 2018 Mar;193:276-283
pubmed: 28689758
Trends Neurosci. 2017 Sep;40(9):536-554
pubmed: 28818303
Epilepsy Behav. 2017 Nov;76:56-62
pubmed: 28927715
Front Neurol. 2017 Sep 08;8:469
pubmed: 28943860
Hippocampus. 2018 Feb;28(2):121-135
pubmed: 29150979
Cureus. 2017 Oct 1;9(10):e1735
pubmed: 29209582
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1618-E1626
pubmed: 29382760
Sci Rep. 2018 Feb 26;8(1):3602
pubmed: 29483603
Neurosci Biobehav Rev. 2018 Jul;90:260-271
pubmed: 29729285
J Affect Disord. 2019 Apr 15;249:159-168
pubmed: 30772743
CNS Drugs. 2019 Mar;33(3):283-291
pubmed: 30784026
J Affect Disord. 2019 Apr 18;253:224-231
pubmed: 31054448
J Pharmacol Exp Ther. 1976 Jun;197(3):697-702
pubmed: 932999

Auteurs

Zeinab Gharaylou (Z)

Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Lida Shafaghi (L)

Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Ali Oghabian (MA)

Neuroimaging and Analysis Group, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Ali Yoonessi (A)

Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Abbas Tafakhori (A)

Imam Khomeini Hospital, Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran.

Esmaeil Shahsavand Ananloo (E)

Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Mahmoudreza Hadjighassem (M)

Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.

Classifications MeSH